Literature DB >> 11305973

Genomics and the pathophysiology of heart failure.

J J Hwang1, V J Dzau, C C Liew.   

Abstract

Heart failure is not a single disease entity, but a syndrome with various causes, including hypertension, ischemic and congenital heart disease, cardiomyopathy, and myocarditis. Because of the multiple etiologies and secondary adaptations contributing to heart failure, the study of the cellular and molecular mechanisms underlying the development and progression of this syndrome has been rather challenging. Much has been learned about the remodeling processes in heart failure, which involve complex interactions among numerous mediators in signaling and regulatory pathways. The Human Genome Project and related projects have provided a preliminary database for a genome-wide analysis of complex polygenic disorders such as heart failure. With the aid of expressed sequence tag technology and microarray applications, both known and previously uncharacterized genes involved in the induction and regression of cardiac hypertrophy and its progression to heart failure can be analyzed simultaneously. Deciphering the complexity of sequence-structure-function relationships in heart failure is a goal for the future, and will require advances in structural biology, proteomics, and computational technology. In this review, we summarize the cellular and molecular aspects of heart failure, and how recent applications of genomic technologies have been successful in achieving a more complete portrait of gene expression in this pathologic state.

Entities:  

Mesh:

Year:  2001        PMID: 11305973     DOI: 10.1007/s11886-001-0023-z

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  62 in total

1.  PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.

Authors:  S O Marx; S Reiken; Y Hisamatsu; T Jayaraman; D Burkhoff; N Rosemblit; A R Marks
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

2.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.

Authors:  T Taigen; L J De Windt; H W Lim; J D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 3.  15 years of heart-failure trials: what have we learned?

Authors:  B M Massie
Journal:  Lancet       Date:  1998-08       Impact factor: 79.321

4.  Calcineurin inhibitors and cardiac hypertrophy.

Authors:  Z Luo; K G Shyu; A Gualberto; K Walsh
Journal:  Nat Med       Date:  1998-10       Impact factor: 53.440

Review 5.  Alterations of calcium-regulatory proteins in heart failure.

Authors:  G Hasenfuss
Journal:  Cardiovasc Res       Date:  1998-02       Impact factor: 10.787

6.  Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.

Authors:  C V Thomas; M L Coker; J L Zellner; J R Handy; A J Crumbley; F G Spinale
Journal:  Circulation       Date:  1998-05-05       Impact factor: 29.690

7.  Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu----Val mutation and a 403Arg----Gln mutation.

Authors:  N D Epstein; G M Cohn; F Cyran; L Fananapazir
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

8.  Inflammation influences vascular remodeling through AT2 receptor expression and signaling.

Authors:  M Akishita; M Horiuchi; H Yamada; L Zhang; G Shirakami; K Tamura; Y Ouchi; V J Dzau
Journal:  Physiol Genomics       Date:  2000-01-24       Impact factor: 3.107

9.  Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene.

Authors:  M Satoh; M Takahashi; T Sakamoto; M Hiroe; F Marumo; A Kimura
Journal:  Biochem Biophys Res Commun       Date:  1999-08-27       Impact factor: 3.575

10.  Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice.

Authors:  Y Sato; D G Ferguson; H Sako; G W Dorn; V J Kadambi; A Yatani; B D Hoit; R A Walsh; E G Kranias
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

View more
  4 in total

1.  Matters of the heart transcriptome: a brief history of cardiovascular genomics.

Authors:  Pilar M Labordé-Lahoz
Journal:  Tex Heart Inst J       Date:  2002

2.  Chronic inhibition of the Na+/H+ - exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling.

Authors:  A Baartscheer; M Hardziyenka; C A Schumacher; C N W Belterman; M M G J van Borren; A O Verkerk; R Coronel; J W T Fiolet
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

3.  Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray.

Authors:  J David Barrans; Paul D Allen; Dimitrios Stamatiou; Victor J Dzau; Choong-Chin Liew
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

4.  Leptin signaling in the failing and mechanically unloaded human heart.

Authors:  Kenneth R McGaffin; Christine S Moravec; Charles F McTiernan
Journal:  Circ Heart Fail       Date:  2009-08-19       Impact factor: 8.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.